Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
FDA clears 2 new solutions, rules on omecamtiv mecarbil for HFrEF | AI model uses DNA to predict AFib, HF
Thursday, March 2, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

Regulatory Roundup: FDA clears 2 new solutions, declines to approve omecamtiv mecarbil for HFrEF

Read our monthly recap of FDA-related news items from the world of cardiovascular medicine. 

READ MORE >
The Millipede 088 Access Catheter. Image courtesy of Perfuze. FDA clearance.
Share on Twitter Share on Facebook Share on Linkedin

Regulatory Roundup: FDA clears 2 new solutions, declines to approve omecamtiv mecarbil for HFrEF

Share on Twitter Share on Facebook Share on Linkedin
The Millipede 088 Access Catheter. Image courtesy of Perfuze. FDA clearance.
Read our monthly recap of FDA-related news items from the world of cardiovascular medicine. 
READ MORE >

Heart failure specialist Sean Pinney named new chief of cardiology at Mount Sinai Morningside

The move represents a return of sorts for Pinney, who served Mount Sinai in a variety of leadership roles from 2004 to 2020.

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Heart failure specialist Sean Pinney named new chief of cardiology at Mount Sinai Morningside

Share on Twitter Share on Facebook Share on Linkedin
The move represents a return of sorts for Pinney, who served Mount Sinai in a variety of leadership roles from 2004 to 2020.
READ MORE >

AI model uses DNA to predict AFib, heart failure

Scientists were able to identify a total of 21 genes linked to cardiovascular conditions such as AFib and heart failure.

READ MORE >
artificial intelligence AI deep learning
Share on Twitter Share on Facebook Share on Linkedin

AI model uses DNA to predict AFib, heart failure

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence AI deep learning
Scientists were able to identify a total of 21 genes linked to cardiovascular conditions such as AFib and heart failure.
READ MORE >

Featured Articles

Medtronic, Abbott share late-breaking TAVR data at CRT 2023

Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.

READ MORE >
Medtronic CoreValve Evolute
Share on Twitter Share on Facebook Share on Linkedin

Medtronic, Abbott share late-breaking TAVR data at CRT 2023

Share on Twitter Share on Facebook Share on Linkedin
Medtronic CoreValve Evolute
Both vendors used the four-day conference as an opportunity to provide key updates about their TAVR valves.
READ MORE >

Popular artificial sweetener associated with greater risk of heart attack, stroke

The new study, led by a team of Cleveland Clinic specialists, was published in Nature Medicine. 

READ MORE >
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
Share on Twitter Share on Facebook Share on Linkedin

Popular artificial sweetener associated with greater risk of heart attack, stroke

Share on Twitter Share on Facebook Share on Linkedin
The World Health Organization has published a new guideline recommending against the use of artificial sweeteners such as aspartame and sucralose to lose weight or reduce the risk of noncommunicable diseases.
The new study, led by a team of Cleveland Clinic specialists, was published in Nature Medicine. 
READ MORE >

How cardiologists can address health disparities in their communities

Incoming 2023-2024 American College of Cardiology president Hadley Wilson, MD, shared insights on how to create health equity through grassroots community outreach programs.

READ MORE >
Incoming 2023-2024 American College of Cardiology (ACC) president Hadley Wilson, MD, shares insights on how to create health equity through both ACC programs and hospital grassroots community outreach programs. He outlines four programs his heart hospital is piloting in its community in Charlotte, North Carolina.
Share on Twitter Share on Facebook Share on Linkedin

How cardiologists can address health disparities in their communities

Share on Twitter Share on Facebook Share on Linkedin
Incoming 2023-2024 American College of Cardiology (ACC) president Hadley Wilson, MD, shares insights on how to create health equity through both ACC programs and hospital grassroots community outreach programs. He outlines four programs his heart hospital is piloting in its community in Charlotte, North Carolina.
Incoming 2023-2024 American College of Cardiology president Hadley Wilson, MD, shared insights on how to create health equity through grassroots community outreach programs.
READ MORE >

In Case You Missed It

ChatGPT and cardiology: A close look at the strengths and weaknesses of AI chatbots

Ashish Sarraju, MD, a cardiologist with Cleveland Clinic, discussed his recent research on ChatGPT, its potential to change patient care and more. 

READ MORE >
A team of cardiologists from Cleveland Clinic and Stanford University recently tested ChatGPT, the popular artificial intelligence (AI) model, to see if it could accurately answer questions about preventive cardiology and cardiovascular disease. The model performed well, only missing a handful of questions, and the researchers concluded that ChatGPT showed considerable potential. Cleveland Clinic cardiologist Ashish Sarraju, MD, was the lead author of that study. #ChartGPT
Share on Twitter Share on Facebook Share on Linkedin

ChatGPT and cardiology: A close look at the strengths and weaknesses of AI chatbots

Share on Twitter Share on Facebook Share on Linkedin
A team of cardiologists from Cleveland Clinic and Stanford University recently tested ChatGPT, the popular artificial intelligence (AI) model, to see if it could accurately answer questions about preventive cardiology and cardiovascular disease. The model performed well, only missing a handful of questions, and the researchers concluded that ChatGPT showed considerable potential. Cleveland Clinic cardiologist Ashish Sarraju, MD, was the lead author of that study. #ChartGPT
Ashish Sarraju, MD, a cardiologist with Cleveland Clinic, discussed his recent research on ChatGPT, its potential to change patient care and more. 
READ MORE >

Medtronic’s new extravascular ICD gains key approval

Unlike other ICDs, the lead for this new-look device is placed under the patient's breastbone, outside of their heart and veins. 

READ MORE >
Medtronic shared some good news with attendees at ESC Congress 2022 in Barcelona, the annual meeting of the European Society of Cardiology, noting that its Extravascular Implantable Cardioverter Defibrillator (EV ICD) system met its safety endpoints in a global clinical trial. Medtronic EV ICD clinical trial safety endpoints ESC Congress 2022 #ESC #ESC2022 #ESC22
Share on Twitter Share on Facebook Share on Linkedin

Medtronic’s new extravascular ICD gains key approval

Share on Twitter Share on Facebook Share on Linkedin
Medtronic shared some good news with attendees at ESC Congress 2022 in Barcelona, the annual meeting of the European Society of Cardiology, noting that its Extravascular Implantable Cardioverter Defibrillator (EV ICD) system met its safety endpoints in a global clinical trial. Medtronic EV ICD clinical trial safety endpoints ESC Congress 2022 #ESC #ESC2022 #ESC22
Unlike other ICDs, the lead for this new-look device is placed under the patient's breastbone, outside of their heart and veins. 
READ MORE >

In Other News

Dual source CT scanners shown to expedite treatment in emergency settings

Dual source CT scanners can eliminate the need for beta blockers to control heart rates during coronary CTA exams.  

READ MORE >
Share on Twitter Share on Facebook Share on Linkedin

Dual source CT scanners shown to expedite treatment in emergency settings

Share on Twitter Share on Facebook Share on Linkedin
Dual source CT scanners can eliminate the need for beta blockers to control heart rates during coronary CTA exams.  
READ MORE >

Eli Lilly caps insulin costs at $35 per month

The company announced price reductions of 70% for its most commonly prescribed insulins.

READ MORE >
diabetes
Share on Twitter Share on Facebook Share on Linkedin

Eli Lilly caps insulin costs at $35 per month

Share on Twitter Share on Facebook Share on Linkedin
diabetes
The company announced price reductions of 70% for its most commonly prescribed insulins.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme